BR112019000982A2 - formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il)-1h-imidazol-2-carboxamida - Google Patents

formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il)-1h-imidazol-2-carboxamida

Info

Publication number
BR112019000982A2
BR112019000982A2 BR112019000982-5A BR112019000982A BR112019000982A2 BR 112019000982 A2 BR112019000982 A2 BR 112019000982A2 BR 112019000982 A BR112019000982 A BR 112019000982A BR 112019000982 A2 BR112019000982 A2 BR 112019000982A2
Authority
BR
Brazil
Prior art keywords
tetramethylthetrahydro
dimethylcyclohex
imidazol
pyran
carboxamide
Prior art date
Application number
BR112019000982-5A
Other languages
English (en)
Inventor
Breslin David
E. Fawzy Nagy
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112019000982A2 publication Critical patent/BR112019000982A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

a presente descrição discute formas cristalinas de 4-ciano-n-[2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il]-1h-imidazol-2-carboxamida.
BR112019000982-5A 2016-07-18 2017-07-17 formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il)-1h-imidazol-2-carboxamida BR112019000982A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662363622P 2016-07-18 2016-07-18
US62/363,622 2016-07-18
PCT/US2017/042310 WO2018017444A1 (en) 2016-07-18 2017-07-17 Crystalline forms of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide

Publications (1)

Publication Number Publication Date
BR112019000982A2 true BR112019000982A2 (pt) 2019-05-14

Family

ID=59631847

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000982-5A BR112019000982A2 (pt) 2016-07-18 2017-07-17 formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il)-1h-imidazol-2-carboxamida

Country Status (16)

Country Link
US (1) US10314821B2 (pt)
EP (1) EP3484872B1 (pt)
JP (1) JP2019521159A (pt)
KR (1) KR20190026910A (pt)
CN (1) CN109952296A (pt)
AR (1) AR109079A1 (pt)
AU (1) AU2017299506B2 (pt)
BR (1) BR112019000982A2 (pt)
CA (1) CA3031230A1 (pt)
EA (1) EA201990320A1 (pt)
ES (1) ES2935647T3 (pt)
MA (1) MA45685A (pt)
MX (2) MX2019000749A (pt)
TW (1) TWI752980B (pt)
UY (1) UY37338A (pt)
WO (1) WO2018017444A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094077A1 (en) * 2020-10-30 2022-05-05 Athenex R&D, Llc Polymorphisms of hm30181 mesylate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3240B1 (ar) * 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
EP2215482A2 (en) * 2007-10-31 2010-08-11 Janssen Pharmaceutica N.V. Biomarker for assessing response to fms treatment
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
MX365315B (es) * 2013-03-15 2019-05-29 Janssen Pharmaceutica Nv Derivados de piridina sustituidos útiles como inhibidores de c-fms quinasa.
CN105283185A (zh) * 2013-03-15 2016-01-27 詹森药业有限公司 用于治疗何杰金氏淋巴瘤的4-氰基-n-(2-(4，4-二甲基环己-1-烯-1-基)-6-(2，2，6，6-四甲基四氢-2h-吡喃-4-基)吡啶-3-基)-1h-咪唑-2-酰胺

Also Published As

Publication number Publication date
KR20190026910A (ko) 2019-03-13
EA201990320A1 (ru) 2019-06-28
AU2017299506B2 (en) 2021-08-05
AU2017299506A1 (en) 2019-02-07
US10314821B2 (en) 2019-06-11
AR109079A1 (es) 2018-10-24
MX2019000749A (es) 2019-08-29
EP3484872B1 (en) 2022-11-30
CA3031230A1 (en) 2018-01-25
UY37338A (es) 2018-01-31
MA45685A (fr) 2019-05-22
JP2019521159A (ja) 2019-07-25
TW201808941A (zh) 2018-03-16
US20180133197A1 (en) 2018-05-17
CN109952296A (zh) 2019-06-28
MX2021006739A (es) 2021-07-15
WO2018017444A1 (en) 2018-01-25
TWI752980B (zh) 2022-01-21
ES2935647T3 (es) 2023-03-08
EP3484872A1 (en) 2019-05-22

Similar Documents

Publication Publication Date Title
DK3497081T3 (da) Fremgangsmåde til fremstilling af 4-ammonium-2,2,6,6-tetraalkylpiperidinylsalte
MA43998A (fr) 2-(het)aryl-imidazolyl-carboxamides substitués utilisés comme pesticides
DK3402782T3 (da) 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decanderivater
MA45554A (fr) Fusions de binucléase optimisées.
HRP20181112T1 (hr) Supstituirani derivati azaspiro(4,5)dekana
ITUB20169914A1 (it) Configurazione intelligente di trattore/attrezzo.
IT201700032302A1 (it) Gruppo di regolazione
BR112019000982A2 (pt) formas cristalinas de 4-ciano-n-(2-(4,4-dimetilciclo-hex-1-en-1-il)-6-(2,2,6,6-tetrametiltetra-hidro-2h-piran-4-il)piridina-3-il)-1h-imidazol-2-carboxamida
MX2016016127A (es) Formas cristalinas.
DK3630729T3 (da) Pyrimidinforbindelse
UY37339A (es) Formas de sal de 4-ciano-n-(2-(4,4-dimetilciclohex-1-en-1-il)-6-(2,2,6,6-tetrametiltetrahidro-2h-piran-4-il)piridin-3-il)-1himidazol-2-carboxamida y composiciones que las contienen
MX2020006006A (es) Polimorfos cristalinos de {(2s,3r)-1-[(2s)-2-{5-[(2r,5r)-1-{3,5-di fluoro-4-[4-(4-fluorofenil)piperidin-1-il]fenil}-5-(6-fluoro-2-{( 2s)-1-[n-(metoxicarbonil)-o-metil-l-treonil]pirrolidin-2-il}-1h-b enzimidazol-5-il)pirrolidin-2-il]-6-fluoro-1h-benzimidazol-2-il}p irrolidin-1-il]-3-metoxi-1-oxobutan-2-il}carbamato de metilo.
DK3592723T3 (da) Fremgangsmåde til fremstilling af 3,3,3-trifluorprop-1-en
ES1177734Y (es) Andamio de fachada.
ITUA20163609A1 (it) "micro-cogeneratore".
UY36363A (es) Compuesto heterocíclico fusionado
ES1280134Y (es) Elemento de sujeción de gafas.
CL2018001247S1 (es) Torno de control de acceso.
CL2019003097S1 (es) Mochila.
CL2019003096S1 (es) Mochila.
CL2019000905S1 (es) Mochila.
DK3638653T3 (da) Fremgangsmåde til fremstilling af 3,4-dichlor-n-(2-cyanophenyl)-5-isothiazolcarboxamid
GB201718303D0 (en) Photobrief, the future of intelligent photo search
UA114708U (uk) Тяговий привід електробуса
IT201700044533A1 (it) Capo di abbigliamento multifunzionale.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]